Nuvation Bio Inc. (NUVB)
| Market Cap | 2.21B +176.5% |
| Revenue (ttm) | 143.05M +1,205.5% |
| Net Income | -145.99M |
| EPS | -0.42 |
| Shares Out | 348.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275,043 |
| Open | 6.50 |
| Previous Close | 6.49 |
| Day's Range | 6.38 - 6.55 |
| 52-Week Range | 2.18 - 9.75 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 12.33 (+94.17%) |
| Earnings Date | Aug 6, 2026 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua... [Read more]
Financial Performance
In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $12.33, which is an increase of 94.17% from the latest price.
News
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announ...
RBC looks for Nuvation shares to appreciate as safusidenib data builds
RBC Capital analyst Leonid Timashev notes Nuvation Bio (NUVB) has reported 40-month follow-up data for their glioma drug – safusidenib, which is a novel treatment for IDHmutant gliomas, a severe…
Nuvation Bio Slides: Corporate presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on July 20, 2026.
Nuvation Bio announces data from the Phase 2 J201 study
Nuvation Bio (NUVB) announced updated positive long-term follow-up data from the Phase 2, or J201, study of safusidenib in patients with chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma...
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up New Phase 3 study to evaluate safusi...
3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts
Some early-stage growth names now sit in the under-$10 range, such as AbCellera Biologics ($ABCL), Serve Robotics ($SERV), and Nuvation Bio ($NUVB). These low-priced stocks carry risk, but each is…
Nuvation Bio price target lowered to $19 from $20 at RBC Capital
RBC Capital lowered the firm’s price target on Nuvation Bio (NUVB) to $19 from $20 and keeps an Outperform rating on the shares as part of a broader research note…
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announc...
Nuvation Bio announces MHRA in UK approves MAA for taletrectinib
Nuvation Bio (NUVB) announced that the Medicines and Healthcare products Regulatory Agency in the United Kingdom has validated the Marketing Authorisation Application submitted by its partner Eisai Co...
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.
Nuvation Bio prices upsized offering of $250M of convertible senior notes
Nuvation Bio (NUVB) “announced the pricing of its underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032. The aggregate principal amount of th...
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing ...
Nuvation Bio falls -10.1%
Nuvation Bio (NUVB) is down -10.1%, or -65c to $5.81.
Nuvation Bio files to sell $200M of Convertible Senior Notes due 2032
Nuvation Bio (NUVB) announced its intent to offer, subject to market conditions and other factors, $200M aggregate principal amount of Convertible Senior Notes due in 2032 in an underwritten offering.
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announ...
Nuvation Bio Slides: Corporate presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Nuvation Bio Transcript: Jefferies Global Healthcare Conference 2026
IBTROZI dominates the ROS1 lung cancer market with unmatched efficacy, long response duration, and strong CNS benefits, backed by guideline changes and patient-reported outcomes. Safusidenib advances in all IDH1 glioma subgroups, with promising results and new studies. The company maintains strong finances and disciplined business development.
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hun...
Nuvation Bio’s Ibtrozi shows improved quality of life in NSCLC trial
Nuvation Bio (NUVB) announced new patient-reported outcomes data from the pivotal TRUST-II study of Ibtrozi – taletrectinib – in patients with advanced ROS1-positive non-small cell lung cancer, or NSC...
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment Cognitive function scores improved or remained ...
Nuvation Bio Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
IBTROZI is experiencing robust first-line growth and is expected to meet or exceed consensus targets, driven by strong efficacy and increasing physician adoption. Pipeline assets like safusidenib are advancing in underserved glioma populations, with key data expected next year.
Nuvation Bio Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by a strong quorum. No questions were raised, and voting results will be filed with the SEC within four business days.
Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2026
IBTROZI drives strong revenue growth via increased first-line patient share, enhanced testing, and superior efficacy. New guidelines and state mandates expand the market. Safusidenib shows superior efficacy in glioma, with pivotal trials underway and large commercial potential. The company is well-capitalized to advance its pipeline and pursue disciplined business development.
Nuvation Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
IBTROZI leads the ROS1 NSCLC market with best-in-class efficacy, expanding into the adjuvant setting and driving strong revenue growth. Safusidenib shows superior results in IDH1 gliomas, with pivotal trial readouts ahead. A new DDC program update is expected later this year.
Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC
Nuvation Bio (NUVB) announced the completion of process tech transfer and product introduction to Thermo Fisher (TMO) for Ibtrozi – taletrectinib – to treat advanced or metastatic ROS1-positive non-sm...